Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar 24;11(2):22.
doi: 10.3390/antib11020022.

Emerging Role of Antibody-Drug Conjugates and Bispecific Antibodies for the Treatment of Multiple Myeloma

Waqqas Tai  1 , Ahsan Wahab  2 , Diana Franco  3 , Zunairah Shah  4 , Aqsa Ashraf  5 , Qurrat-Ul-Ain Abid  6 , Yaqub Nadeem Mohammed  7 , Darshan Lal  8 , Faiz Anwer  9
Affiliations
Review

Emerging Role of Antibody-Drug Conjugates and Bispecific Antibodies for the Treatment of Multiple Myeloma

Waqqas Tai et al. Antibodies (Basel). .

Abstract

Multiple myeloma (MM) is characterized by malignant proliferation of malignant plasma cells; it is the second most common hematological malignancy associated with significant morbidity. Genetic intricacy, instability, and diverse clinical presentations remain a barrier to cure. The treatment of MM is modernized with the introduction of newer therapeutics agents, i.e., target-specific monoclonal antibodies. The currently available literature lacks the benefits of newer targeted therapy being developed with an aim to reduce side effects and increase effectiveness, compared to conventional chemotherapy regimens. This article aims to review literature about the current available monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies for the treatment of MM.

Keywords: antibody; antibody drug conjugate; bispecific antibody; immunotherapy; multiple myeloma; targeted therapy.

PubMed Disclaimer

Conflict of interest statement

FA reports personal fees from Bristol Myers Squibb as a speaker and a fee from Janssen pharmaceutical as an advisory board member; this fee was not related to the submitted work. Without receiving direct funding, served as the local principal investigator for Allogene Therapeutics, Celgene, GlaxoSmithKline, and Bristol Myers Squibb; has a consulting or advisory role for Seattle Genetics, Incyte Corporation Speakers’ Bureau, Company: Incyte Corporation; receives travel and accommodations expenses from Seattle Genetics, Incyte; receives honoraria from Incyte, Company: Seattle Genetics; and received research funding from Seattle Genetics, Company: Celgene, Acetylon Pharmaceuticals, Millennium, Astellas Pharma and AbbVie; and reports no other potential conflicts of interest for this work. The other authors report no conflicts of interest for this work.

References

    1. Joshua D.E., Bryant C., Dix C., Gibson J., Ho J. Biology and therapy of multiple myeloma. Med. J. Aust. 2019;210:375–380. - PubMed
    1. Riccomi G., Fornaciari G., Giuffra V. Multiple myeloma in paleopathology: A critical review. Int. J. Paleopathol. 2019;24:201–212. - PubMed
    1. Palumbo A., Anderson K. Multiple myeloma. N. Engl. J. Med. 2011;11:1046–1060. - PubMed
    1. Landgren O. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: Biological insights and early treatment strategies. Hematol. Am. Soc. Hematol. Educ. Program. 2013;2013:478–487. - PubMed
    1. Kyle R.A., Therneau T.M., Rajkumar S.V., Larson D.R., Plevak M.F. Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: The Original Mayo Clinic series 25 years later. Mayo Clin. Proc. 2004;7:859–866. - PubMed

LinkOut - more resources